ArticleCNS neuroscience & therapeutics2026
Sleep Deprivation Induces Glial Dysfunction, Synaptic Loss, Metabolic Imbalance, and Cognitive Impairment in 12-Month-Old Mice: Protective Effects of D30.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSleep deprivation (SD) has been increasingly implicated in age-related cognitive decline. However, the mechanisms linking SD duration to progressive disruption of glial homeostasis, synaptic vulnerability, and metabolic dysregulation remain poorly defined.
methodsWe employed 12-month-old Thy1-EGFP and Cx3CR1-EGFP mice to investigate the effects of short-term sleep deprivation (SSD) and long-term sleep deprivation (LSD) on neuronal architecture, microglial morphology, and astrocytic homeostasis. Quantitative analyses included dendritic spine density, synaptic protein expression, glial morphological and transcriptional markers, and untargeted plasma metabolomics. The neuroprotective effects of D30, a novel small molecule compound, were also evaluated.
resultsSSD induced relatively transient oxidative stress and glial suppression, whereas LSD led to sustained reductions in dendritic spine density, synaptic protein levels, and microglial/astrocytic morphological complexity. LSD further disrupted mitochondrial metabolism, notably involving the TCA cycle, AMPK-associated signaling, and lipid homeostasis. Treatment with D30 significantly ameliorated LSD-induced deficits by preserving glial homeostatic features, restoring synaptic protein expression, maintaining dendritic spine density, and rebalancing systemic metabolism, ultimately improving cognitive performance.
conclusionsLSD impairs glial homeostatic integrity and synaptic stability in association with systemic metabolic dysfunction in middle-aged mice. D30 effectively alleviates these impairments, highlighting its potential as a protective intervention for chronic SD-related neurocognitive dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.